Overview
Interius BioTherapeutics develops gene-therapy approaches to treat blood cancers by generating CAR T cells inside the patient’s body (in vivo). Its delivery platform targets specific cells to trigger the patient’s immune cells to become CAR T cells without removing cells for outside manipulation or using pre-conditioning chemotherapy. This approach aims to simplify CAR T treatment and potentially improve safety by avoiding ex vivo engineering and conditioning, differentiating it from traditional CAR T therapies. The company plans to advance its in vivo CAR T platform for hematologic malignancies and to expand to other diseases, while pursuing development and eventual product sales.
Work here?Claim your company
Simplify's take
What believers are saying
- INVISE completed first-patient dosing and remains active, not recruiting as of November 2026.
- CTIS lists 10 enrolled patients and primary completion anticipated in October 2026.
- Kite expects interim safety and proof-of-concept data at a scientific meeting in 2026.
What critics are saying
- Germany and Spain ended the trial early, signaling execution or tolerability problems.
- Only 10 patients enrolled versus 34 planned, slowing evidence generation.
- If INT2104 disappoints, Kite can terminate the platform and bury Interius's thesis.
What makes Interius BioTherapeutics unique
- Interius's LENTIVECTOR delivers CAR transgenes in vivo, skipping leukapheresis, manufacturing, and lymphodepletion.
- INT2104 targets CD20-positive B cells with a single IV infusion.
- Kite paid $350 million in 2025, validating the platform's strategic value.
Help us improve and share your feedback! Did you find this helpful?